May 20, 2012

Baker’s Dozen Trying to Beat the Odds in Pancreatic Cancer

Pancreatic Cancer Image

November marks Pancreatic Cancer Awareness Month – a baker’s dozen are trying to beat the odds in treating the disease.

Drug Development Spotlight: The mTOR’s New Clothes?

MD Becker Partners' Life Science Digest: Drug Development Spotlight - The mTOR’s New Clothes?

In 1837, Hans Christian Andersen authored a short tale titled The Emperor’s New Clothes.  The main character, so enamored by his appearance and his clothing that he had a different suit for every hour of the day, was swindled by a pair of weavers purporting that they could create clothing from a magical fabric that [...]

Past Pitfalls and Potential Promise for Pancreatic Cancer

pancreatic_slide

Next month [November] marks Pancreatic Cancer Awareness Month.  Visibility for the disease is already on the rise due to recent celebrity victims, including Apple’s Steve Jobs and Hollywood actor Patrick Swayze. According to the American Cancer Society, pancreatic cancer is a devastating disease with the worst mortality rate and an overall 5-year survival rate lower [...]

Investment Opportunities with Five Frontline Therapies for AML

473462-small

Acute myelogenous leukemia [AML] is a fast-growing cancer of the blood and bone marrow.  Unformed cells called myeloblasts, or “blasts,” reside in the bone marrow and normally become a particular kind of cell – a white blood cell, red blood cell, or platelet.  In AML, abnormal blasts produce white blood cells that do not function [...]

Monoclonal Antibody Companies Command Premiums

Monoclonal antibody image from MD Becker Partners

Monoclonal antibodies, which have been approved for immunological, anti-infective, ophthalmic, cancer and other categories, represent one of the most successful therapeutic drug classes.  Ten monoclonal antibodies have been approved for cancer therapy alone, including three blockbuster products sold by the Roche Group (RHHBY) – Avastin® [bevacizumab], Rituxan® [rituximab], and Herceptin® [trastuzumab] that collectively represented nearly [...]